Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.

Slides:

Advertisements

Similar presentations

Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.

Advertisements

University Hospital La Paz

PLATINUM A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Objective To evaluate.

Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.

TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.

Columbia / CRF DES vs. BMS Meta-Analysis Kirtane et al, Circ 2009;119:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk of Stroke With Coronary Artery Bypass Graft.

From: Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm.

Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.

DRug Eluting Bbsorbable Metal Scaffold (DREAMS)

Issues and Current Situations in the Development of Endovascular Treatment Devices for Pediatric Cardiology in the US – US Industry Dan Gutfinger, MD,

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

Disclosures Runlin Gao has received a research grant

Figure 1 Flow diagram of systematic review

Figure 1 Causes of bioprosthetic valve dysfunction.

Latvian Centre of Cardiology real-life registry

Runlin Gao, M.D. On behalf of ABSORB China Investigators

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds

<sup>d</sup>Stands for as long as it is well tolerated.

Bioresorbale Stents Just an Alternative or One-Way Street?

Figure 1. Meta-analysis of prospective biomarker studies examining associations between eicosapentaenoic acid (EPA) and total, low-, and high-grade prostate.

Evaluation and use of coronary bioresorbable scaffolds:

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.

Figure 1 The flowchart depicts the total number of procedures in the Western Denmark Heart Registry (WDHR) and the exclusion of patients; NPR, National.

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

on behalf of the ABSORB II Investigators

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis S Hajibandeh, S Hajibandeh,

American College of Cardiology Presented by Dr. Stephan Windecker

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year.

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

Figure 1 Milestones in coronary angioplasty

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty Nicholas Candy, MBBS, Eugene Ng, MBBS, Ramesh.

Coronary artery bypass grafting is superior to first-generation drug-eluting stents for unprotected left main coronary artery disease: An updated meta-analysis.

European Society of Cardiology Scientific Congress, September 2006

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

David J.A. Jenkins et al. JACC 2018;71:

Gregg W. Stone, MD Columbia University Medical Center

Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review Gennaro D’Amico, Juan Carlos Garcia-Pagan,

Figure 1 Mechanism of mortality benefit associated with radial access

Infrainguinal angioplasty with drug-eluting stents and balloons

Angiographic outcomes of radial artery versus saphenous vein in coronary artery bypass graft surgery: A meta-analysis of randomized controlled trials

Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease Hidde Jongsma, MD, Joost.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Toshiaki Toyota et al. JCIN 2017;10:27-37

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Yin-Shu Chang, MD, Jia-Xiang Wang, MD, PhD, Da-Wei Chang, PhD

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: A meta-analysis of randomized and nonrandomized.

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target American.

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

(p for non-inferiority < 0.001)

The American College of Cardiology Presented by Dr. A. Abazid

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Presentation transcript:

Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support and molecular weight and mass of the polymer over time. For the magnesium scaffold, the content of magnesium and calcium phosphate (a conversion product) over time is shown. PLLA, poly-L-lactic acid. From: Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary Eur Heart J. Published online August 28, 2017. doi:10.1093/eurheartj/ehx488 Eur Heart J | The article has been co-published with permission in the European Heart Journal [DOI: 10.1093/eurheartj/ehx488] and EuroIntervention [DOI: 10.4244/EIJ20170912-01]. All rights reserved in respect of European Heart Journal, © The Author 2017, and in respect of EuroIntervention © The Author 2017. The articles are identical except for minor stylistic and spelling differences in keeping with each journal s style. Either citation can be used when citing this article.

Figure 2 Meta-analysis of differences in late lumen loss between bioresorbable scaffolds and conventional drug-eluting stents in trials with angiographic surveillance scheduled at 6–12 months follow-up. Plots of weighted mean difference in (A) in-device and (B) in-segment late loss. The boxes/diamonds indicate the point estimate and the left and the right ends of the lines the 95% confidence interval (CI). BVS, Absorb bioresorbable vascular scaffold; EES, everolimus-eluting stent.<sup>25</sup> From: Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary Eur Heart J. Published online August 28, 2017. doi:10.1093/eurheartj/ehx488 Eur Heart J | The article has been co-published with permission in the European Heart Journal [DOI: 10.1093/eurheartj/ehx488] and EuroIntervention [DOI: 10.4244/EIJ20170912-01]. All rights reserved in respect of European Heart Journal, © The Author 2017, and in respect of EuroIntervention © The Author 2017. The articles are identical except for minor stylistic and spelling differences in keeping with each journal s style. Either citation can be used when citing this article.

Figure 3 Risk of target lesion failure and stent/scaffold thrombosis at follow-up of 2 years or more in meta-analysis of seven randomized controlled trials comparing bioresorbable scaffolds and conventional drug-eluting stents. (A) target lesion failure; (B) stent/scaffold thrombosis. Odds ratios for target lesion failure with polymeric bioresorbable scaffolds vs. EES. The diamonds indicate the point estimate and the left and the right ends of the lines the [95% confidence interval, CI]. BVS, bioresorbable stent (i.e. Absorb polymeric bioresorbable scaffolds); EES, everolimus-eluting stent.<sup>29</sup> From: Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary Eur Heart J. Published online August 28, 2017. doi:10.1093/eurheartj/ehx488 Eur Heart J | The article has been co-published with permission in the European Heart Journal [DOI: 10.1093/eurheartj/ehx488] and EuroIntervention [DOI: 10.4244/EIJ20170912-01]. All rights reserved in respect of European Heart Journal, © The Author 2017, and in respect of EuroIntervention © The Author 2017. The articles are identical except for minor stylistic and spelling differences in keeping with each journal s style. Either citation can be used when citing this article.

Figure 4 Task Force recommended clinical evaluation plan for bioresorbable scaffolds. EP, end point; FU, follow-up; RCT, randomized controlled trial; *the manufacturer must submit and have approved by the notified body a plan for post-market clinical follow up in the form of a large-scale, randomized trial ± a large-scale clinical registry. From: Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary Eur Heart J. Published online August 28, 2017. doi:10.1093/eurheartj/ehx488 Eur Heart J | The article has been co-published with permission in the European Heart Journal [DOI: 10.1093/eurheartj/ehx488] and EuroIntervention [DOI: 10.4244/EIJ20170912-01]. All rights reserved in respect of European Heart Journal, © The Author 2017, and in respect of EuroIntervention © The Author 2017. The articles are identical except for minor stylistic and spelling differences in keeping with each journal s style. Either citation can be used when citing this article.